Tuesday, October 19, 2021  | 12 Rabiulawal, 1443
Samaa TV
Facebook Twitter Youtube
HOME > Health

BioNTech warns against delaying second vaccine dose beyond 21 days

Britain, Denmark and Germany are considering delaying doses

SAMAA | - Posted: Jan 5, 2021 | Last Updated: 10 months ago
SAMAA |
Posted: Jan 5, 2021 | Last Updated: 10 months ago

Photo: AFP

Listen to the story
German firm BioNTech warned Tuesday there is no data backing the "safety and efficacy" of delaying the second shot of its Covid-19 vaccine beyond three weeks, as some countries push back the jab to give more people their first dose. BioNTech, which developed the vaccine with US giant Pfizer, said its clinical data showing 95% efficacy was based on a two-dose schedule separated by 21 days. "The safety and efficacy of the vaccine has not been evaluated on different dosing schedules," it said. "Although data… demonstrated that there is a partial protection from the vaccine as early as 12 days after the first dose, there is no data to demonstrate that protection after the first dose is sustained after 21 days." Faced with limited supplies of the vaccines, Denmark said Monday it would space out the jabs by up to six weeks, while Britain has said it would wait up to 12 weeks before giving the second jab. Germany too is mulling pushing back the second shot to beyond 21 days. Proponents say that practice would allow more of the population to get their first jab. "While decisions on alternative dosing regimens reside with health authorities, we believe a second dose is required to provide the maximum protection against the disease," BioNTech said. Mainz-based BioNTech said it remains committed to continuing "dialogue with regulators, health authorities and governments" on "any public health decisions".
FaceBook WhatsApp

German firm BioNTech warned Tuesday there is no data backing the “safety and efficacy” of delaying the second shot of its Covid-19 vaccine beyond three weeks, as some countries push back the jab to give more people their first dose.

BioNTech, which developed the vaccine with US giant Pfizer, said its clinical data showing 95% efficacy was based on a two-dose schedule separated by 21 days.

“The safety and efficacy of the vaccine has not been evaluated on different dosing schedules,” it said.

“Although data… demonstrated that there is a partial protection from the vaccine as early as 12 days after the first dose, there is no data to demonstrate that protection after the first dose is sustained after 21 days.”

Faced with limited supplies of the vaccines, Denmark said Monday it would space out the jabs by up to six weeks, while Britain has said it would wait up to 12 weeks before giving the second jab.

Germany too is mulling pushing back the second shot to beyond 21 days.

Proponents say that practice would allow more of the population to get their first jab.

“While decisions on alternative dosing regimens reside with health authorities, we believe a second dose is required to provide the maximum protection against the disease,” BioNTech said.

Mainz-based BioNTech said it remains committed to continuing “dialogue with regulators, health authorities and governments” on “any public health decisions”.

 
HOME  
 
 
RELATED STORIES

Tell us what you think:

Your email address will not be published.

FaceBook WhatsApp
 
 
 
 

MOST READ
MOST READ
Imtiaz Super Market robbed of nearly a million: police
Here’s Karachi’s traffic plan for 12th Rabiul Awwal
Policeman martyred in explosion outside Quetta university
DG ISI Gen Faiz Hameed briefs COAS on security: ISPR
Govt moves to cut taxes on commodities for price reduction
IMF talks, PPP, PDM announce protests, petrol price hikes
Malala writes to Taliban one month after girls’ school ban
Inflation to go down from March next year: Asad Umar
 
 
 
 
 
About Us   |   Anchor Profiles   |   Online Advertising   |   Contact Us   |   Feedback   |   Apps   |   FAQs   |   Authors   |   Comment Policy
Facebook   |   Twitter   |   Instagram   |   YouTube   |   WhatsApp